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Abstract
Aims Mitral annuloplasty using the Carillon Mitral Contour System (CMCS) reduces secondary mitral regurgitation (SMR) and
leads to reverse left ventricular remodelling. The aim of this study was to evaluate the effect of the CMCS on the mitral valve
annulus (MA) and left atrial volume (LAV).
Methods and results We retrospectively evaluated the data of all patients treated with the CMCS at our centre. Using trans-
thoracic echocardiography, MA diameters were assessed by measuring the anterolateral to posteromedial extend (ALPM) and
the anterior to posterior (AP) dimensions, respectively. Also, LAV and left ventricular end-diastolic volume (LVEDV) were
assessed. Patients were examined at three time points: baseline, at 20–60 days (30dFUP), and at 9–15 months (1yFUP), using
paired analysis. From July 2014 until March 2019, 75 cases of severe SMR were treated using CMCS. Cases in which other de-
vices were used in combination (COMBO therapy, n = 35) or in which the device could not be implanted (implant failure, n = 3)
were excluded, leaving 37 patients in the present analysis. Analysis at 30dFUP showed a significant reduction of 16% in the
mean ALPM diameter (7.27 ± 5.40mm) and 15% in the AP diameter (6.57 ± 5.33mm). Analysis of LAV also showed a significant
reduction of 21% (36.61 ± 82.67 mL), with no significant change in LVEDV. At 1yFUP, the reduction of both the mean ALPM
diameter of 14% (6.24 ± 5.70 mm) and the mean AP diameter of 12% (5.46 ± 4.99 mm) remained significant and stable.
The reduction in LAV was also maintained at 23% (37.03 ± 56.91 mL). LAV index was significantly reduced by 17% at 30dFUP
(15.44 ± 40.98mL/m2) and by 13% at 1yFUP (11.56 ± 31.87mL/m2), respectively. LVEDV index showed no significant change at
30dFUP and a non-significant 10% reduction at 1yFUP (17.75 ± 58.79 mL/m2).
Conclusions The CMCS successfully treats symptomatic SMR with a stable reduction of not only the AP diameter of the MA,
but the current study also demonstrates an additional reduction of the ALPM dimension at both 30dFUP and 1yFUP. We have
also shown for the first time that LAV and LAV index are significantly reduced at both 30dFUP and 1yFUP and a non-significant
positive remodelling of the LVEDV. This positive left atrial remodelling has not been looked for and demonstrated in earlier
randomized studies of CMCS.
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Introduction
Secondary mitral regurgitation (SMR) is prevalent in patients
with chronic heart failure, increasing mortality and
morbidity.1–4 Percutaneous mitral valve repair has become
a sound alternative to cardiac surgery in high-risk patients
with severe mitral regurgitation,5,6 with one recent edge-to-
edge therapy recently associated with a reduction of mortal-
ity following successful treatment.7
One of the components of SMR is dilation of the mitral
valve annulus (MA) and increased left atrial volume (LAV).8
The Carillon Mitral Contour System® (CMCS; Cardiac Dimen-
sions, Inc., Kirkland, WA, USA) is the only device having CE ap-
proval to treat mitral regurgitation by addressing MA dilation
through indirect annuloplasty, utilizing the proximity of the
coronary sinus (CS) to the MA. Several studies have shown
the safety and efficacy of the device with reduction in mitral
regurgitation grade and improvement in exercise capacity,
quality of life,9–11 and left ventricular (LV) reverse
remodelling.11,12 The device also reduces MA dilation, but
there are no data on the treatment effect on left atrial (LA)
enlargement. LA enlargement, however, is associated with a
heightened risk of cardiovascular events and mortality.13,14
In this study, we sought to elucidate the effect of CMCS
therapy on MA dimensions, LV end-diastolic volume (LVEDV),
and LAV.
Methods
Study population
We retrospectively evaluated the data of all patients
treated with the CMCS system (n = 75). All patients were
treated for symptomatic mitral regurgitation ≥2+ and were
not eligible for cardiac surgery as assessed by the heart
team. Therapy strategy was either CMCS alone (MONO,
n = 40) or a combination therapy (COMBO, n = 35), either
adding edge-to-edge therapy, that is, MitraClip® (MC; Ab-
bott Vascular, Santa Clara, CA, USA) or NeoChord
(NeoChord, Inc., St. Louis Park, MN, USA). The present anal-
ysis focuses on those patients treated with the CMCS only
(MONO) (Figure 1). The study was approved by the local
ethics committee (2019-14692).
Percutaneous mitral valve repair
The details of the procedure have been reported
previously.15,16 In short, under fluoroscopic guidance, the de-
livery catheter was advanced to the right atrium via the right
internal jugular vein. Anchor size and device length were de-
termined by measuring the CS, opacified by direct CS contrast
injection (Figure 2A). To implant the device, the distal anchor
is placed at a suitable location, following which tension on the
MA is achieved by pulling the delivery system by 4 to 6 cm.
Finally, after confirming no impingement of either the circum-
flex artery or the right coronary artery by selective arteriogra-
phy, the device is locked in position by deploying the
proximal anchor (Figure 2B) and released. All patients were
placed under general anaesthesia. Following the procedure,
patients were monitored for at least 24 h.
Echocardiography
Using transthoracic echocardiography, MA was assessed by
measuring the anterolateral to posteromedial extend (ALPM)
in the apical two-chamber view and the anterior to posterior
(AP) dimension in the apical three-chamber view, respec-
tively. LAV and LVEDV were measured using the biplane ap-
proach in the apical four-chamber and two-chamber views,
respectively (Figure 3). Measurements were taken during
end-diastole. Indices were calculated using the formula de-
scribed by Mosteller.17 The ultrasound machines used were
Philips iE33 and Epiq 7C (Philips, Andover, MA, USA) and GE
Vivid E95 (GE Healthcare, Chicago, IL, USA), and analysis
was conducted using IntelliSpace Cardiovascular and QLAB
(Philips). Measurements were taken pre-procedure (base-
line), at 20–60 days (30dFUP), and at 9–15 months (1yFUP).
Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics
Version 23 (IBM Corp., Armonk, NY, USA). The Kolmogorov–
Smirnov test was used to test for normality following which
Student’s t test was performed on normally distributed data,
while the Wilcoxon test was used for non-normally distrib-
uted data. P-values smaller than 0.05 were considered signif-
icant. Figures were created using IBM SPSS Statistics Version
23 and Microsoft Excel 16.9 (Microsoft, Redmond, WA, USA).
Results
Patient characteristics
From July 2014 until March 2018, 75 patients underwent
treatment for mitral regurgitation, using CMCS. Of these, 72
were successfully implanted, with the MONO approach used
in 37, all in SMR. Demographical and echocardiographic data
are depicted in Tables 1 and 2, respectively. Follow-up rate at
30dFUP was 86% (n = 32) and at 1YFUP was 56% (n = 21), re-
spectively. Results are shown in Figures 4 and 5 and Table 3.
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Figure 1 Patient selection and grouping. COMBO, either CMCS and MC
®
or CMCS and NeoChord
®
were both implanted, respectively; MONO, only
CMCS was implanted.
Figure 2 Sizing and placement of CMCS: (A) venogram of CS for sizing of CMCS and parallel coronary angiogram, visualizing the right circumflex cor-
onary artery, unobstructed by the CMCS device; (B) placement of proximal anchor; (C) cinching of CMCS and parallel visualization of right circumflex
coronary artery; and (D) final placement.
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Annulus diameter
Analysing data at the 30dFUP, there was a significant reduc-
tion of 16.0% in the mean ALPM diameter [n = 32, from
43.53 ± 3.82 to 36.25 ± 3.71 mm, a mean reduction of
7.28 ± 5.40 mm, confidence interval (CI) 5.32 to 9.22;
P < 0.001], as well as a 15.0% reduction in the AP diameter
(n = 32, from 41.56 ± 4.53 to 34.99 ± 5.47mm, a mean reduc-
tion of 6.57 ± 5.33 mm, CI 4.65 to 8.49; P < 0.001). At the
1yFUP, there was a persistently significant 14% reduction of
the mean ALPM diameter (n = 21, from 43.81 ± 3.94 to
37.57 ± 5.23 mm, a reduction of 6.24 ± 5.70 mm, CI 3.64 to
8.83; P < 0.001). The reduction of the mean AP diameter
remained at 12% (from 42.41 ± 3.45 to 36.95 ± 5.83 mm,
n = 21, a reduction of 5.46 ± 4.99 mm, CI 3.19 to 7.73;
P < 0.001).
There were no statistical differences of ALPM and AP diam-
eters in between 30dFUP and 1yFUP, respectively (data not
shown).
Left ventricular and left atrial volumes
Analysis of LAV at 30dFUP showed a significant reduction
of 21% [n = 32, -36.61 ± 82.67 mL, CI 6.81 to 66.41
(169.96 ± 129.76 vs. 133.35 ± 65.68); P = 0.018]. With 23%,
reduction of LAV remained statistically significant at 1yFUP
[n = 21, 37.03 ± 56.91 mL, CI 11.13 to 62.94
(157.60 ± 73.22 vs. 120.57 ± 48.89); P = 0.007]. LAV index
(LAVi) was also significantly reduced at 30dFUP by 17%
[-15.44 ± 40.98 mL/m2, CI 3.27 to 27.60 (90.08 ± 65.02 vs.
74.64 ± 36.65); P = 0.014] and at 1yFUP by 13%
[-11.56 ± 31.87 mL/m2, CI 0.26 to 22.86 (83.68 ± 39.93 vs.
72.12 ± 37.28); P = 0.045], respectively.
Concerning LVEDV, there were no statistically relevant re-
ductions at 30dFUP [n = 32, 4.31 ± 52.33 (175.55 ± 91.45
vs. 171.23 ± 77.81); P = 0.644] nor at 1yFUP [n = 21,
13.72 ± 58.42 (176.99 ± 104.24 vs. 163.27 ± 92.53);
P = 0.295], respectively. Also, we did not observe a significant
change in LVEDV index (LVEDVi) at 30dFUP [0.50 ±
48.10 mL/m2, CI 14.32 to 13.32 (177.05 ± 84.93 vs.
177.55 ± 78.75); P = 0.942]. At the 1yFUP, there was a 10%
reduction, showing a tendency but not reaching statistical
significance [-17.75 ± 58.79 mL/m2, CI 2.15 to 37.64
(171.15 ± 88.44 vs. 153.40 ± 88.43), P = 0.079] (Figure 6).
There were no statistical differences of LAV, LAVi, LVEDV,
and LVEDVi in between 30dFUP and 1yFUP, respectively (data
not shown).
Discussion
This is the first study to evaluate the positive remodelling
effect of the CMCS on both MA diameters, that is, AP
Figure 3 Echocardiography—baseline (top row) vs. 1 year follow-up (bottom row): assessment of biplane left atrial volume in four-chamber view (A, D)
and apical two-chamber view (B, E) and measurement of mitral valve area diameters in the apical two-chamber view (anterolateral to posteromedial
extend, B, E) and the apical three-chamber view (anterior to posterior, C, F). In this example, left atrial volume is reduced by approximately 26% (190
vs. 140 mL), while anterolateral to posteromedial extend decreased by 23% (46 vs. 35 mm) and AP 30% (39 vs. 27 mm), respectively.
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and ALPM, and LAV as well as LAVi in a large, single-
centre cohort of 37 patients suffering from symptomatic
severe SMR.
Dilation of the MA is a typical finding in SMR.3,18 A
characteristic anatomic feature is loss of the saddle shape
of the MA, thus increasing leaflet stress contributing to
malcoaptation.19
Reduction of MA diameter by ~15% using the CMCS has al-
ready been demonstrated in the TITAN studies.10,11 Our results
confirm those findings, showing a reduction of AP by 15% at
30dFUP and 12% at 1yFUP, respectively. However, in this
study, we also observed a persistent reduction in the perpen-
dicular ALPM dimension at 30dFUP and at 1yFUP. A change in
the AP diameter has also already been shown in other trans-
catheter techniques. For instance, in the context of edge-to-
edge leaflet therapy in SMR, one study evaluating the immedi-
ate effect of the therapy on mitral valve geometrics demon-
strated a significant reduction in the AP diameter, although
here too, the ALPM dimensions were not improved.20
Our observation of additional reduction of the ALPM diam-
eter is novel and not in contrast with these findings. In edge-
to-edge therapy, change of the AP diameter alone is not sur-
prising, as the reductive force of the therapy is directed in this
direction only. To have the greatest effect in indirect
annuloplasty using the Carillon system, the distal anchor is de-
ployed as deep into the CS as possible, in order to encircle the
greatest possible proportion of the mitral annulus from the left
to right trigone. Hence, the cinching force is executed not only
in the AP dimension but also in the ALPM plane. In the TITAN-
II-study, for instance, as AP was thought to be most impacted
by SMR, only the AP diameter (not ALPM) was assessed.11
Left atrial remodelling, incorporating changes of atrial
geometric structure and haemodynamic function, is the result
Table 1 Baseline demographics
Sex 37
Male 20 (54%)
Female 17 (46%)
Age at procedure (years) 71.08 ± 11.09
Height (cm) 161.67 ± 0.40
Weight (kg) 76.03 ± 28.36
BMI (kg/m2) 26.10 ± 8.93
BSA (m2) 1.90 ± 0.26
Logarithmic EuroSCORE 20.28
Arterial hypertension 28 (75%)
Hyperlipoproteinaemia 35 (94%)
Pulmonary hypertension 21 (56%)
Coronary artery disease 28 (75%)
PCI 25 (67%)
CABG 1 (2%)
Previous myocardial infarction 21 (56%)
Type of cardiomyopathy
DCM 12 (32%)
ICM 21 (56%)
LACM 4 (10%)
Stroke 5 (13%)
Peripheral artery disease 9 (24%)
Atrial fibrillation 21 (56%)
PM or ICD 10 (27%)
Diabetes mellitus 9 (24%)
Chronic pulmonary disease 8 (21%)
Chronic renal failure 7 (18%)
Dialysis 2 (5%)
Previous valve replacement 10 (27%)
SAVR 5 (13%)
TAVR 5 (13%)
Medication
Anti-platelets 24 (64%)
Oral anticoagulation 21 (56%)
ACEI or ARB 28 (75%)
Beta-blockers 28 (75%)
Digitalis 4 (10%)
Loop diuretics 29 (78%)
Spironolcatone 14 (37%)
Statin 18 (48%)
NYHA class
II 7 (18%)
III 19 (51%)
IV 3 (8%)
LVEF 35.29 ± 13.17%
Grade of mitral regurgitation
2+ 3 (8%)
3+ 31 (84%)
4+ 3 (8%)
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin
receptor blocker; BMI, body mass index; BSA, body surface area;
CABG, coronary artery bypass graft; DCM, dilated cardiomyopathy;
ICD, implantable cardioverter/defibrillator; ICM, ischaemic cardio-
myopathy; LACM, left atrial cardiomyopathy; LVEF, left ventricular
ejection fraction, the standard deviation is shown; NYHA, New York
Health Association; PCI, percutaneous coronary intervention; PM,
pacemaker; SAVR, surgical aortic valve replacement; TAVR, trans-
catheter aortic valve replacement.
Continuous variables are shown as mean ± standard deviation and
categorical variables as number (%). Pulmonary hypertension is de-
fined as a systolic pulmonary artery pressure of >55 mmHg as
assessed by echocardiography. Anti-platelets included aspirin,
clopidogrel, prasugrel, or ticagrelor or a combination of these.
Table 2 Baseline echo characteristics
Overall
Baseline—all n = 37
ALPM (mm) 43.24 ±4.13
AP (mm) 41.77 ±4.38
LAV (mL) 175.20 ±127.05
LVEDV (mL) 177.59 ±90.32
Baseline (30 day follow-up visitors) n = 32
ALPM (mm) 43.53 ± 3.82
AP (mm) 41.56 ± 4.53
LAV (mL) 169.96 ± 129.76
LAVi (mL/m2) 90.08
LVEDV (mL) 175.54 ± 91.45
LVEDVi (mL/m2) 177.05 ± 84.93
Baseline (1 year follow-up visitors) n = 21
ALPM (mm) 43.80 ± 3.94
AP (mm) 42.41 ± 3.45
LAV (mL) 157.60 ± 73.22
LAVi (mL/m2) 83.68 ± 39.93
LVEDV (mL) 176.99 ± 92.53
LVEDVi (mL/m2) 171.14 ± 88.44
ALPM, anterolateral to posteromedial extend; AP, anterior to pos-
terior; LAV, left atrial volume; LAVi, left atrial volume index; LVEDV,
left ventricular end-diastolic volume; LVEDVi, left ventricular
end-diastolic volume index.
Continuous variables are shown as mean ± standard deviation and
categorical variables as number (%).
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of the combined stress forces on the LA wall including those
due to increased LV end-diastolic pressure, atrial arrhythmias,
and mitral annulus deformation or strain as well as valve
dysfunction21 and is also influenced by activation of the
renin–angiotensin–aldosterone system, depletion of atrial na-
triuretic peptide, and increased LA pressure.22 These combined
effects lead not only to impaired LA systolic function and dia-
stolic compliance, and electric conduction abnormalities, but
also to changes in the molecular structure21,23 prompting the
term atrial cardiomyopathy.24 Therefore, the drivers of LA re-
modelling mirror those of LV remodelling as seen in heart fail-
ure. LA remodelling is associated with a heightened risk of
cardiovascular events and mortality.13 In this study, we have
demonstrated a significant decrease of LAV, both as absolute
measurements and as indexed to body surface area (LAVi).
The remodelling starts as early as 30 days after the procedure
and the decrease remains stable at 1yFUP.25,26
This effect of the Carillon device on LV remodelling
with a reduction of LVEDV of 10.42 mL in our series has
recently been confirmed in the larger and randomized
REDUCE FMR study.11,12,27 Our data, with similar baseline
LV volumes as well as the LVEDVi, demonstrate a similar
reduction at 1 year, suggesting that the lack of statistical
significance in our data is likely due to an insufficient
patient cohort size.
The ‘reverse LA remodelling’ that we demonstrated in this
study could represent a novel marker of beneficial changes in
halting progressive LA dilatation as a syndrome and conse-
quence of heart failure, possibly preceding in time the re-
verse remodelling of the LV demonstrated as a significant
benefit of Carillon Mitral Contour System in the randomized
REDUCE FMR trial.27
Limitations
The present dataset should be viewed in the light of its
retrospective nature and single-centre origin, and hidden
confounders cannot be accounted for.28 However, each oper-
ator followed standard procedural guidance, and the echo-
cardiograms were performed by operators disconnected
with the device procedure and analysed in a blinded fashion.
Nevertheless, the data are hypothesis generating rather than
Figure 4 Evolution of mitral valve annulus: dimensions of anterior to posterior (AP) (top row) and anterolateral to posteromedial extend (ALPM) (bot-
tom row) as demonstrated by boxplot (A, C) and direct comparison (B, D).
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conclusive.29 A prospectively designed randomized trial
would be needed in order to elucidate the effect of the ther-
apy on mitralvalve annulus dimensions and reverse atrial re-
modelling. Further answers might be given by the recently
launched sham-controlled, double-blind Carillon Food and
Drug Administration Trial (NCT03142152), aiming to recruit
350 (check) patients taking optimal medical therapy to the
Carillon device or sham.
Figure 5 Evolution of left atrial (LA) volume (top row) and LA volume index (bottom row) as demonstrated by boxplot (A, C) and direct comparison
(B, D).
Table 3 Results
n Reduction P
Baseline vs. 30dFUP
ALPM (mm) 32 7.27 ± 5.40, CI 5.32 to 9.22 <0.001
AP (mm) 32 6.57 ± 5.33, CI 4.65 to 8.49 <0.001
LAV (mL) 32 36.61 ± 82.67, CI 6.81 to 66.41 0.018
LAVi (mL/m2) 32 15.44 ± 40.98, CI 3.27 to 27.60 0.014
LVEDV (mL) 32 4.31 ± 52.33, CI 14.55 to 23.18 0.644
LVEDVi (mL/m2) 32 0.50 ± 48.10, CI 14.32 to 13.32 0.942
Baseline vs. 1yFUP
ALPM (mm) 21 6.24 ± 5.70, CI 3.64 to 8.83 <0.001
AP (mm) 21 5.46 ± 4.99, CI 3.19 to 7.73 <0.001
LAV (mL) 21 37.03 ± 56.91, CI 11.13 to 62.94 0.007
LAVi (mL/m2) 21 11.56 ± 31.87, CI 0.26 to 22.86 0.045
LVEDV (mL) 21 13.72 ± 58.42, CI 12.88 to 40 0.295
LVEDVi (mL/m2) 21 17.75 ± 58.79, CI 2.15 to 37.64 0.079
ALPM, anterolateral to posteromedial extend; AP, anterior to posterior; CI, confidence interval; LAV, left atrial volume; LAVi, left atrial vol-
ume index; LVEDV, left ventricular end-diastolic volume; LVEDVi, left ventricular end-diastolic volume index.
Continuous variables are shown as mean ± standard deviation and categorical variables as number (%).
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Conclusions
The CMCS reduces the diameter of the dilated mitral annulus
as previously demonstrated in the AP dimension and also in
APLM dimensions in our cohort. Furthermore, we saw an
early and profound reduction in LAV and LAVi preceding sim-
ilar effects on LVEDV and LVEDVi, suggesting that a reduction
in mitral valve regurgitation leads via a reduction in LA pres-
sure and geometry to a significant reverse left atrial remodel-
ling that is visible as early as 30dFUP following a significant
and stable reduction at 1 year follow-up.
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